ReviewJAMA oncology2020
Moving From Cancer Burden to Cancer Genomics for Smoldering Myeloma: A Review.
Review in JAMA oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 54 citations in OpenAlex.
- Dynamic risk stratification in smoldering multiple myeloma: Integrating evolving biomarkers with the 2/20/20 Model.HemaSphere · 2026Article
- Genomics Define Malignant Transformation in Myeloma Precursor Conditions.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Article
- Navigating the evolving management of smoldering multiple myeloma.HemaSphere · 2026Review
- Unique molecular assay (UMA): a next-generation sequencing targeted panel for efficient and comprehensive genomic profiling and risk stratification of multiple myeloma.Haematologica · 2025Article
- Article
- Temporal genomic dynamics shape clinical trajectory in multiple myeloma.Nature genetics · 2025Article
- Article
- Article
- [Progress in risk stratification and treatment of high-risk smoldering multiple myeloma].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2024Review
- Genomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Article
- Article
- Inference of genomic lesions from single-cell RNA-seq in myeloma improves functional intraclonal and interclonal analysis.Blood advances · 2024Article
- Article
- Is aggressive treatment of smoldering myeloma the path to curing myeloma?Blood advances · 2023Article
- Monoclonal gammopathy of increasing significance: time to screen?Haematologica · 2023Review
- IL5RA as an immunogenic cell death-related predictor in progression and therapeutic response of multiple myeloma.Scientific reports · 2023Article
- Prevalence of smoldering multiple myeloma based on nationwide screening.Nature medicine · 2023Article
- Single-Cell RNA Sequencing for the Detection of Clonotypic V(D)J Rearrangements in Multiple Myeloma.International journal of molecular sciences · 2022Article
- Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 3 countries.
Funding
Abstract
Importance: All patients who develop multiple myeloma have a preceding asymptomatic expansion of clonal plasma cells, clinically recognized as monoclonal gammopathy of undetermined significance or smoldering multiple myeloma (SMM). During the past decade, significant progress has been made in the classification and risk stratification of SMM. Observations: This review summarizes current clinical challenges and discusses available models for risk stratification in the context of SMM. Owing to several novel, more effective, and less toxic drugs, these aspects are becoming increasingly important to identify patients eligible for early treatment. However, all proposed criteria were built around indirect markers of disease burden and therefore are generally able to identify a fraction of patients with SMM in whom transformation to multiple myeloma and genomic subclonal diversification are already happening. In contrast, next-generation sequencing approaches have the potential to identify myeloma precursor disease that will progress even before the major clonal expansion and progression, providing a potential base for more effective treatment and better precision regarding the optimal timing of treatment initiation. Conclusions and Relevance: Owing to modern technologies, in the near future, prognostic models derived from genomic signatures independent of the disease burden will allow better identification of the optimal timing to treat a plasma cell clonal disorder at the very early stages, when the chances of eradication are higher.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.